Abstracts tagged "Lupus and epidemiologic methods"

Abstract Number: 1097 • 2018 ACR/ARHP Annual Meeting
Spatial-Time Cluster Analysis of SLE Disease Activity
George Stojan¹, Anton Kvit², Frank Curriero² and Michelle Petri³, ¹Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ²Bloomberg School of Public Health, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Cluster detection is an essential tool in the public health domain with the goal of detecting anomalous clusters of disease cases. We performed a…
Abstract Number: 58 • 2015 ACR/ARHP Annual Meeting
Attribution of Cause of End-Stage Renal Disease Among Systemic Lupus Erythematosus Patients
Laura Plantinga¹, Cristina Drenkard¹, Stephen Pastan² and S. Sam Lim³, ¹Department of Medicine, Emory University, Atlanta, GA, ²Department of Medicine, Division of Renal Medicine, Emory University, Atlanta, GA, ³Emory University School of Medicine, Atlanta, GA
Background/Purpose: The attributed cause of end-stage renal disease (ESRD) in the United States Renal Data System (USRDS) is often used to identify systemic lupus erythematosus…
Abstract Number: 1237 • 2015 ACR/ARHP Annual Meeting
The Incidence and Prevalence of Systemic Lupus Erythematous in a Defined Population in United Arab Emirates
Ali Al Dhanhani¹, Omran Bakoush², Mukesh Agarwal³ and Yusra Othman⁴, ¹Dept. Internal Medicine,, Assistant profesor, UAE University, Al Ain, United Arab Emirates, ²Internal Medicine, Associate Professor , UAE University, Al Ain, United Arab Emirates, ³Professor, UAE University, Al Ain, United Arab Emirates, ⁴Tawam Hospital, Al Ain, United Arab Emirates
Background/Purpose: There is a paucity of information about the incidence and prevalence of systemic lupus erythematosus (SLE) in United Arab Emirates (UAE) and Arab countries.…
Abstract Number: 2788 • 2014 ACR/ARHP Annual Meeting
Preliminary Population- Based Incidence and Prevalence Estimates of SLE: The California Lupus Surveillance Project
Maria Dall'era¹, Kurt Snipes², Miriam Cisternas³, C. Gordon⁴ and Charles G. Helmick⁵, ¹Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ²California Department of Public Health, Sacramento, CA, ³MGC Data Services, San Diego, CA, ⁴Rheumatology (East Wing), Medical School, Birmingham, United Kingdom, ⁵National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA
Background/Purpose: Previous estimates of prevalence and incidence of systemic lupus erythematosus (SLE) in the United States have varied widely. The California Lupus Surveillance Project (CLSP)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].